ProfileGDS5678 / 1417239_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 96% 96% 96% 96% 93% 95% 96% 96% 96% 96% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.7734896
GSM967853U87-EV human glioblastoma xenograft - Control 29.1017696
GSM967854U87-EV human glioblastoma xenograft - Control 38.9573396
GSM967855U87-EV human glioblastoma xenograft - Control 48.9862596
GSM967856U87-EV human glioblastoma xenograft - Control 59.0408396
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.5036696
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.7588693
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5852995
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.8373296
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.772796
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.7544696
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.0912296
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.6841396
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.9867796